Mitochondrial creatine kinase as a tumor-associated marker

Area of Science:

• Biochemistry
• Oncology
• Clinical Chemistry

Background:

• Malignant tumors are associated with various biochemical changes.
• Creatine kinase (CK) is an enzyme involved in cellular energy homeostasis.
• Mitochondrial creatine kinase (CKm) has been investigated as a potential biomarker.

Purpose of the Study:

• To investigate the presence and significance of mitochondrial creatine kinase (CKm) in the sera of cancer patients.
• To determine if CKm levels correlate with tumor type, stage, treatment, or patient prognosis.

Main Methods:

• Serum samples from 167 cancer patients were analyzed for the presence of CKm.
• CKm detection was performed using biochemical assays.
• Patient data including tumor type, stage, treatment, and survival were collected.

Main Results:

• CKm was detected in 66 out of 167 patients (40%).
• CKm was found in patients with various cancers, including hepatic, gastric, lung, and mammary carcinomas.
• Patients with CKm had a 1.7 times higher mortality rate compared to CKm-negative patients.
• CKm levels were highest in gastric carcinoma patients.
• Most CKm-positive patients had metastatic/infiltrating disease and were undergoing chemotherapy.

Conclusions:

• CKm may serve as a marker for biological factors associated with a poor prognosis in cancer patients.
• CKm presence is not solely indicative of primary or metastatic tumors.
• Elevated CKm, particularly in gastric cancer, warrants further investigation as a prognostic indicator.